The primary objective is to evaluate the cardiovascular profile and the risk of thrombotic events in patients affected by Oral Lichen Planus.
Patients with a clinical and histological diagnosis of Oral Lichen Planus
Age > 18 years
Patients who agree to sign the informed consent form
Patients under 18 years of age
Patients who do not agree to sign the informed consent form
Patients without a diagnosis of Oral Lichen Planus
Patients with previously known cardiac diseases
Patients affected by oral lichen planus
Cohort
Prospective
blood sample collection
Other interventionblood sample collection in old patients in order to study the trombophilic risk
Prothrombotic risk evaluation
Primary Outcome Measure 1 Title: Prevalence of Natural Anticoagulant Deficiency * Description: Proportion of patients with Oral Lichen Planus (OLP) showing reduced functional activity of at least one natural anticoagulant (antithrombin III, protein C, or protein S) below the laboratory reference range, measured in plasma samples. * Time Frame: From September 2025 to September 2026 * Unit of Measure: Percentage of participants with abnormal result (%). Primary Outcome Measure 2 Title: Prevalence of Antiphospholipid Antibody Positivity * Description: Proportion of OLP patients with positive antiphospholipid antibodies, defined as anticardiolipin IgG and/or IgM and/or anti-β2-glycoprotein I IgG/IgM above the laboratory cut-off, measured in serum. * Time Frame: From September 2025 to September 2026 * Unit of Measure: Percentage of participants with abnormal result (%).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
